Clinical Trial Update: Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update of riociguat in adult homozygous Delta F508 cystic fibrosis patients was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Riociguat (riociguat)

Snippet

Sponsor: Bayer | Conditions: Cystic Fibrosis | Phase 2 | Status: TERMINATED | Results posted: 2018-03-29